TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $4.43 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.